Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells

Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer

(2022) Taylor P Berke et al.   OncoTargets and Therapy

The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells

(2021) Luisa Klemke et al.   Frontiers in Oncology

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer

(2021) Yang Hu et al.   MOLECULAR CANCER THERAPEUTICS

A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis

(2020) Rohitesh Gupta et al.   Cells

A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell

(2020) Jiaqi Liu et al.   Annals of Translational Medicine

O-glycan recognition and function in mice and human cancers

(2020) Gabrielle E. Cervoni et al.   BIOCHEMICAL JOURNAL

Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis

(2020) Sima Lev   BIOCHEMICAL SOCIETY TRANSACTIONS

Field Cancerization: Definition, epidemiology, risk factors, and outcomes

(2020) Tyler J. Willenbrink et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins

(2020) Karis Tutuska et al.   Cell Death & Disease

Discovery, Biosynthesis, and Heterologous Production of Loonamycin, a Potent Anticancer Indolocarbazole Alkaloid

(2020) Cheng Long Yang et al.   ORGANIC LETTERS

The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy

(2020) Javad Sargolzaei et al.   PHARMACOLOGICAL RESEARCH

Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site

(2020) Shuo Chen et al.   CANCER CELL

Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs

(2020) Emma Baglini et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II

(2019) Joyce H. Lee et al.   Genes

PI3K Inhibitors in Breast Cancer Therapy

(2019) Haley Ellis et al.   Current Oncology Reports

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis

(2018) Galileo A. Gonzalez-Conchas et al.   CANCER TREATMENT REVIEWS

Tumor suppressive role for kinases phosphorylating p53 in the DNA damage-induced apoptosis

(2018) Satomi Yogosawa et al.   CANCER SCIENCE

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

(2014) A. García Fernández et al.   Clinical & Translational Oncology

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

(2014) Heae Surng Park et al.   MODERN PATHOLOGY

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Mucins in pancreatic cancer and its microenvironment

(2013) Sukhwinder Kaur et al.   Nature Reviews Gastroenterology & Hepatology

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

(2013) Binh Vu et al.   ACS Medicinal Chemistry Letters

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

(2013) Christopher D. Wassman et al.   Nature Communications

Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer

(2012) Anita Schwandt et al.   Journal of Thoracic Oncology

A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors

(2010) Muhammad Wasif Saif et al.   ANTI-CANCER DRUGS

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells

(2009) Robert W. Robey et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2

(2009) D P Teufel et al.   ONCOGENE

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors

(2008) Giovanni Luca Beretta et al.   EXPERT OPINION ON THERAPEUTIC TARGETS